Eni subsidiary Versalis and Elevance partner to develop new metathesis technology for bio-chemicals from veg oils
Versalis, the chemical subsidiary of Eni, and Elevance Renewable Sciences, Inc., a producer of specialty chemicals from natural oils (earlier post), signed a Memorandum of Understanding (MoU) to establish a strategic partnership jointly to develop and scale a new metathesis technology to produce bio-chemicals from vegetable oils.
This partnership with Versalis is a natural next step building on the commercially competitive demonstrations of molybdenum-catalyzed metathesis of natural oils that we have achieved in our partnership with XIMO.—K’Lynne Johnson, Elevance CEO
Versalis and Elevance intend to focus on developing and scaling new catalysts, leveraging the significant progress of this technology that has been already accomplished by Elevance. In addition, the partners will assess the design and construction of the first world-scale ethylene metathesis-based production that will utilize renewable oils at the Versalis Porto Marghera site. This will also take advantage of existing infrastructures and production streams.
The market applications of the future bio-chemicals production will be personal care, detergents and cleaners, bio-lubricants and oilfield chemicals.
The bio-based chemicals business is central to Versalis’ new industrial and business approach. The agreement with Elevance will further enhance our capability to progress in green innovation while boosting the transformation of one of our petrochemical sites into a more competitive and long-term sustainable complex, thus creating synergies between the renewable with the petrochemical industries.—Daniele Ferrari, Versalis CEO
Versalis will contribute its extensive skills in catalysis process development and engineering design scale-up and Elevance will bring proprietary know-how regarding metathesis and associated engineering with the use of vegetable oils in producing specialty chemicals for premium applications, leveraging similar projects in the US and Asia.